Zometa European study (ZEUS): Another failed crusade for the holy grail of prostate cancer bone metastases prevention?

European Urology

Volumn 67, Issue 3, 2015, Pages 492-494

  Tombal, Bertrand ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DENOSUMAB; PROSTATE SPECIFIC ANTIGEN; TECHNETIUM 99M; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

BONE METASTASIS; BONE SCINTISCANNING; CANCER RISK; CANCER SURVIVAL; EDITORIAL; GLEASON SCORE; HUMAN; MALE; OSTEOLYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; BONE NEOPLASMS; PROSTATIC NEOPLASMS;

ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; HUMANS; IMIDAZOLES; MALE; PROSTATIC NEOPLASMS;

EID: 84922255874     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2014.03.009     Document Type: Editorial

References (10)

1. J.B. Nelson, W. Love, and J.L. Chin Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer Cancer 113 2008 2478 2487
2. M. Norgaard, A.O. Jensen, J.B. Jacobsen, K. Cetin, J.P. Fryzek, and H.T. Sorensen Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007) J Urol 184 2010 162 167
3. M. Wirth, T. Tammela, and V. Cicalese Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS) Eur Urol 67 2015 482 491
4. M.R. Smith, F. Saad, and R. Coleman Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial Lancet 379 2012 39 46
5. M.R. Smith, R. Cook, K.A. Lee, and J.B. Nelson Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer Cancer 15 117 2011 2077 2085
6. M.R. Smith, F. Kabbinavar, and F. Saad Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer J Clin Oncol 23 2005 2918 2925
7. F.E. Lecouvet, M. Simon, B. Tombal, J. Jamart, B.C. Vande Berg, and P. Simoni Whole-body MRI (WB-MRI) versus axial skeleton MRI (AS-MRI) to detect and measure bone metastases in prostate cancer (PCa) Eur Radiol 20 2010 2973 2982
8. Home page. Choosing Wisely Web site. http://www.choosingwisely.org. Accessed March 3, 2014.
9. D.P. Dearnaley, M.D. Mason, M.K. Parmar, K. Sanders, and M.R. Sydes Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials Lancet Oncol 10 2009 872 876
10. K. Miller, J.W. Moul, and M. Gleave Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer Prostate Cancer Prostatic Dis 16 2013 187 192